- Home
- HSCS vs BOLT Comparison
HSCS vs BOLT Comparison
Compare HSCS & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSCS
- BOLT
- Stock Information
- Founded
- HSCS 2007
- BOLT 2015
- Country
- HSCS United States
- BOLT United States
- Employees
- HSCS N/A
- BOLT N/A
- Industry
- HSCS Medical Specialities
- BOLT Biotechnology: Pharmaceutical Preparations
- Sector
- HSCS Health Care
- BOLT Health Care
- Exchange
- HSCS Nasdaq
- BOLT Nasdaq
- Market Cap
- HSCS 9.9M
- BOLT 11.5M
- IPO Year
- HSCS 2022
- BOLT 2021
- Fundamental
- Price
- HSCS $3.16
- BOLT $5.80
- Analyst Decision
- HSCS Strong Buy
- BOLT Buy
- Analyst Count
- HSCS 2
- BOLT 4
- Target Price
- HSCS $10.50
- BOLT $34.00
- AVG Volume (30 Days)
- HSCS 25.5K
- BOLT 39.0K
- Earning Date
- HSCS 12-15-2025
- BOLT 11-14-2025
- Dividend Yield
- HSCS N/A
- BOLT N/A
- EPS Growth
- HSCS N/A
- BOLT N/A
- EPS
- HSCS N/A
- BOLT N/A
- Revenue
- HSCS $6,250.00
- BOLT $4,167,000.00
- Revenue This Year
- HSCS N/A
- BOLT N/A
- Revenue Next Year
- HSCS N/A
- BOLT N/A
- P/E Ratio
- HSCS N/A
- BOLT N/A
- Revenue Growth
- HSCS N/A
- BOLT N/A
- 52 Week Low
- HSCS $2.52
- BOLT $4.59
- 52 Week High
- HSCS $6.47
- BOLT $14.00
- Technical
- Relative Strength Index (RSI)
- HSCS 36.80
- BOLT 49.91
- Support Level
- HSCS $3.16
- BOLT $5.61
- Resistance Level
- HSCS $3.43
- BOLT $6.35
- Average True Range (ATR)
- HSCS 0.16
- BOLT 0.36
- MACD
- HSCS -0.04
- BOLT -0.01
- Stochastic Oscillator
- HSCS 1.67
- BOLT 17.05
About HSCS Heart Test Laboratories Inc.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.